Cuu Long Pharmaceutical JSC (DCL) has announced it will contribute capital with State Capital Investment Corporation (SCIC) to the corporation of Benovas oncology JSC with an initial charter capital of 100 billion dong. After establishment, DCL owned 55% of charter capital. SCIC and other partners will hold the rest.
This is the first cancer drug project in Vietnam with German technology following European standards. The project estimated to implement from 2017, with total investment of 1,000 billion for two periods. Under the plan, the time to build and put into operation of the plant is about 4 years, however, even in 2017, DCL will start importing and selling oncology products in Vietnam.
Completion of this plan, DCL will be the first domestic pharmaceutical company which produce those oncology products in Vietnam.
2016 is the 3rd consecutive year DCL achieved impressive growth in revenue and profits. In particular, in 2015, profit after tax increased
more than 91% compared to 2014; 2016, profit after tax increased by 50% compared to 2015.
Cuu Long Pharmaceutical Joint Stock Company has chartered capital of 563 billion VND. 2017, the company plans to put 914 billion in net revenue, profit after tax of 96 billion, respectively up to 24%, , and 7% compared with the number performed in 2016.
